The economics of febrile neutropenia: Implications for the use of golony-stimulating factors

European Journal of Cancer

Volumn 34, Issue 12, 1998, Pages 1857-1864

  Lyman, G H ^a   Kuderer, N ^b   Greene, J ^a   Balducci, L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Costs; Economics; Febrile neutropenia; Granulocyte colony stimulating factor (G CSF)

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR;

ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; DECISION MAKING; FEVER; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; NEUTROPENIA; PATIENT CODING; PRIORITY JOURNAL;

ADULT; AGED; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 0032211332     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00222-6     Document Type: Article

References (39)

1. 1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Int Med 1966, 64, 328-340.
2. 2. Pizzo PA, Hawthorn JW, Heimenz J, et al. A randomized trial comparing cefazidine alone with combination antibiotic therapy in cancer patients with neutropenia and fever. N Engl J Med 1986, 315, 552-558.
3. 3. Gabrilove JL, Jackobowski A, Scher H, et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988, 318, 1414-1422.
4. 4. Morstyn G, Campbell L, Lieschke G. et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989, 7, 1554-1562.
5. 5. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first ten years. Blood 1996, 88, 1907-1929.
6. 6. Maher DW, Graham JL, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Int Med 1994, 121, 492-501.
7. 7. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995, 87, 803-808.
8. 8. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997, 336, 1776-1780.
9. 9. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325, 164-170.
10. 10. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A, 319-324.
11. 11. Rowe JM, Anderson JW, Mazza JJ, et al. A randomised placebo controlled phase III study of GM-CSF in adult patients with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 1995, 86, 457-462.
12. 12. Schmitz N, Linch DC, Dreger P, et al. Filgrastim-mobilized peripheral blood progenitor transplantation in comparison with autologous bone marrow transplantation: results of a randomized phase III trial in lymphoma patients. Lancet 1996, 347, 353-357.
13. 13. Heil G, Dieter H, Sanz MA, et al. Randomized double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997, 90, 4710-4718.
14. 14. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1992, 85, 488-493.
15. 15. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994, 12, 1245-1250.
16. 16. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA-Cancer J Clin 1997, 47, 5-27.
17. 17. Vincenzino JV. Health care costs: market forces and reform. Oncology 1995, 9, 367-374.
18. 18. Schuette HL, Tucker TC, Brown ML, Potosky AC, Samuel T. The costs of cancer care in the United States: implications for action. Oncology 1995, 11, 19-22.
19. 19. Brown ML. The national economic burden of cancer: an update. J Natl Cancer Inst 1990, 82, 1811-1814.
20. 20. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analyses of health care technology: a report on principles. Ann Int Med 1985, 122, 61-70.
21. 21. Schulman KA, Yabroff K. Measuring the cost-effectiveness of cancer care. Oncology 1995, 9, 523-533.
22. 22. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment-guidelines. J Clin Oncol 1996, 14, 671-679.
23. 23. Smith TJ, Hillner BE, Desch CE. Efficacy and cost effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993, 85, 1460-1474.
24. 24. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc 1996, 276, 1172-1177.
25. 25. Weinstein MC, Siegel JE, Gold MR, Kamiet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. J Am Med Assoc 1996, 276, 1253-1258.
26. 26. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analysis. J Am Med Assoc 1996, 276, 1330-1341.
27. 27. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Ger J Cancer 1993, 29, 523-530.
28. 28. Lyman GH, Balducci L. A cost analysis of hemapoietic colony-stimulating factors. Oncology 1995, 9, 85-91.
29. 29. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996, 14, 1957-1960.
30. 30. Lyman GH, Kuderer NM. Incorporation of quality-of-life considerations into decision models for the use of colony-stimulating factors in chemotherapy patients at risk for febrile neutropenia. In Klastersky JA, ed. Febrile Neutropenia. Heidelberg, Springer, 1997, 17-22.
31. 31. Bennett CL, Golub R, Waters TM, Tallman MS, Rowe JM. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997, 15, 227-236.
32. 32. Souêtre E, Qing W, Pénelaud PF. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 1996, 32A, 1162-1165.
33. 33. Faucher C, Le Corroller AG, Blaise D, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994, 14, 895-901.
34. 34. Uyl-deGroot CA, OssenKopple CJ, van Riet AAPM, Rutten FFH. The costs of peripheral blood progenitor cell reinfusion mobilization by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994, 30A, 457-459.
35. 35. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Int Med 1997, 126, 600-607.
36. 36. Le Corroller QA-G, Faucher C, Auperin A, et al. Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease: a randomised economic study. Pharmacoeconomics 1997, 11, 454-463.
37. 37. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphomas. J Clin Oncol 1997, 15, 5-10.
38. 38. McQuaker IG, Hunter AE, Pacey S, et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997, 15, 451-457.
39. 39. Lyman GH, Kuderer NM, Balducci L. Economic impact of granulopoiesis-stimulating agents on the management of febrile neutropenia. Curr Opin Oncol 1998, 10, 291-296.